Shimla Online

Irritable Bowel Syndrome (IBS) Diagnostics Market projected to reach US$ 3,880.91 million by 2028 and to grow at a CAGR of 5.9%

 Breaking News
  • No posts were found

Irritable Bowel Syndrome (IBS) Diagnostics Market projected to reach US$ 3,880.91 million by 2028 and to grow at a CAGR of 5.9%

April 06
16:48 2021
Irritable Bowel Syndrome (IBS) Diagnostics Market projected to reach US$ 3,880.91 million by 2028 and to grow at a CAGR of 5.9%

Irritable Bowel Syndrome (IBS) Diagnostics Market
Irritable bowel syndrome (IBS) diagnostics market was valued at US$ 2,470.61 million in 2020 and is projected to reach US$ 3,880.91 million by 2028; it is expected to grow at a CAGR of 5.9% from 2021 to 2028.

Irritable bowel syndrome (IBS) is defined as a gastro-intestinal disorder causing discomfort in the stomach, along with diarrhea, and constipation. IBS can develop after a severe session of diarrhea (gastroenteritis) caused by bacteria or a virus. IBS might also be associated with a surplus of bacteria in the bowels (bacterial overgrowth). People exposed to stressful events, especially in childhood, tend to have more symptoms of IBS. IBS diagnostics is done through medical history, physical exam, and imaging tests. However, IBS is majorly diagnosed by lactose intolerance tests, breath test for bacterial overgrowth, blood test, and stool test. The tests are done based on symptoms such as constipation-predominant, diarrhea-predominant, or mixed. It can also detect by various imaging tests such as CT Scan or X-ray, upper endoscopy, and colonoscopy.

Based on diagnosis, the global irritable bowel syndrome (IBS) diagnostics market is segmented into laboratory tests and imaging tests. In 2020, the laboratory tests segment held the largest share in the market. Moreover, the segment is expected to hold the largest market share by 2028. The market growth is mainly attributed to the growing prevalence of irritable bowel syndrome (IBS) worldwide, which is likely to continue in the coming years due to disturbances in bowel habits and abdominal pain. This, in turn, is boosting the demand for diagnosis of these diseases worldwide.

Request for Sample PDF Copy at: https://www.theinsightpartners.com/sample/TIPRE00016657/

A few prominent players operating in the irritable bowel syndrome (IBS) diagnostics market are Commonwealth Diagnostics International; Genova Diagnostics; Gemelli Biotech; Prometheus Laboratories; Inova Diagnostics, Inc.; Biohit Oyj; Aerodiagnostics, LLC.; Metabolic Solutions, Inc.; Sysmex Corporation; and Bühlmann Laboratories AG, among others.

The COVID-19 pandemic is estimated to have a significant positive impact on the irritable bowel syndrome (IBS) diagnostics market. Majority of the pharmaceutical companies across the world are engaged in the development of vaccines for COVID-19. Moreover, irritable bowel syndrome (IBS) is frequently triggered by COVID-19 stress. Thus, home testing kits are preferable to laboratory testing as laboratory services may be overwhelmed in the pandemic, which is anticipated to have a positive impact on the other segments of the market in the coming months. However, disruptions in the supply chain caused due to the halt in global operations are hindering the market growth. 

People across the world are witnessing considerable incidence of irritable bowel syndrome. According to the data published by International Foundation for Gastrointestinal Disorders, among all irritable bowel syndrome patients, about 40% of people have mild IBS, around 35% have moderate IBS, and an estimated 25% have severe IBS. Food allergies, developing stages of gastroenteritis, sporadic movements of colon, abnormal composition of serotonin in colon, and mild celiac disease are among the risk factors that cause irritable bowel syndrome. According to a study published on NCBI in 2018, irritable bowel syndrome is estimated to affect around 10–16% of the US population each year. Further, as per the IBS Global Impact Report, in 2016, an estimated mean prevalence of individual countries ranged from 1.1% in France and Iran to 35.5% in Mexico. Latin America had a prevalence rate of 17.5%, Asia 9.6%, North America/Europe/Australia/New Zealand 7.1%, and the Middle East & Africa had a prevalence rate of 5.8%.  Such staggering prevalence of irritable bowel syndrome is likely to boost the irritable bowel syndrome (IBS) diagnostics market during the forecast period.

To cope up against irritable bowel syndrome, the market players are taking constructive steps to create programs to spread awareness among the population. For instance, in 2018, the collaboration of Allergan PLC and Ironwood launched an Interactive Digital Destination platform to encourage sufferers to get educated and act. Similarly, in January 2018, Commonwealth Diagnostics International, Inc. collaborated with American professional golfer, Rob Oppenheim to raise awareness about irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO).

The irritable bowel syndrome (IBS) diagnostics market is projected to witness approvals of diagnostic solutions, which will eventually have a positive impact on the growth of the market. For instance, in June 2019, BÜHLMANN Laboratories AG received United States Food and Drug Administration (FDA) 510(k) clearance for its BÜHLMANN fCAL turbo Automated Calprotectin Test and BÜHLMANN fCAL ELISA Calprotectin Test. According to company estimates, the test is anticipated to observe thriving sales in the global market.

The report segments the global irritable bowel syndrome (IBS) diagnostics market as follows:

Irritable Bowel Syndrome (IBS) Diagnostics Market – by Diagnosis

  • Laboratory Tests
    • Lactose Intolerance Tests
    • Breath Test for Bacterial Overgrowth
    • Stool Tests
    • Blood Tests
  • Imaging Tests
    • CT Scan or X-Ray
    • Upper Endoscopy
    • Colonoscopy

 Irritable Bowel Syndrome (IBS) Diagnostics Market – by Indication

  • Pain and Cramping
  • Diarrhea
  • Constipation
  • Alternating Constipation and Diarrhea

Buy this Report Research @ https://www.theinsightpartners.com/buy/TIPRE00016657/

About Us: 

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact Us:

Call: +1-646-491-9876

Email: [email protected]

Media Contact
Company Name: The Insight Partners
Contact Person: Sameer Joshi
Email: Send Email
Phone: +1-646-491-9876
City: Pune
State: Maharashtra
Country: India
Website: https://www.theinsightpartners.com/

Related Articles